Lifecore’s Withdrawn Intergel Solution Represented 12% Of 2002 Revenues
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical and Johnson & Johnson/Ethicon will investigate adverse events involving the firm's Intergel adhesion prevention solution following a voluntary market withdrawal of the device by J&J March 27
You may also be interested in...
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
Lifecore Biomedical CEO Resigns; Intergel Withdrawal Review Continues
Dennis Allingham's replacement of former Lifecore Biomedical President & CEO James Bracke comes amid an ongoing review of reported adverse events related to the firm's Intergel adhesion barrier